Literature DB >> 5103781

Circulatory collapse following succinylcholine: report of a patient with diffuse lower motor neuron disease.

T P Beach, W A Stone, W Hamelberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5103781

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


× No keyword cloud information.
  8 in total

1.  An index of syndromes and their anaesthetic implications.

Authors:  A E Jones; D A Pelton
Journal:  Can Anaesth Soc J       Date:  1976-03

2.  [Post-succinylcholine hyperkalemia].

Authors:  H Desmeules
Journal:  Can Med Assoc J       Date:  1973-06-23       Impact factor: 8.262

3.  Suxamethonium is dangerous in polyneuropathy.

Authors:  R J Fergusson; D J Wright; R F Willey; G K Crompton; I W Grant
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

Review 4.  [Neuromuscular monitoring in patients with neuromuscular diseases. Options and needs].

Authors:  A Beloiartsev; S Gableske; M Hübler
Journal:  Anaesthesist       Date:  2009-07       Impact factor: 1.041

Review 5.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

6.  Anesthetic management of a patient with spinocerebellar degeneration.

Authors:  Prasanna Vadhanan; Pramod Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

7.  Anaesthesia for ophthalmologic surgical procedures in a patient with advanced amyotrophic lateral sclerosis: a case report.

Authors:  Maciej M Kowalik; Tomasz Smiatacz; Robert Pajuro; Roman Skowroński; Hanna Trocha; Walenty Nyka; Krystyna Raczyńska; Maria Wujtewicz
Journal:  Cases J       Date:  2008-11-20

8.  Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex: A case report.

Authors:  Hea Rim Chun; Jinhun Chung; Nan Seol Kim; A Joo Kim; Suro Kim; Kyu Sik Kang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.